CR Bard, Inc. v. Smiths Medical ASD, Inc.

CourtDistrict Court, D. Delaware
DecidedNovember 16, 2020
Docket1:20-cv-01543
StatusUnknown

This text of CR Bard, Inc. v. Smiths Medical ASD, Inc. (CR Bard, Inc. v. Smiths Medical ASD, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
CR Bard, Inc. v. Smiths Medical ASD, Inc., (D. Del. 2020).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF UTAH

MEMORANDUM DECISION AND C.R. BARD, INC., a New Jersey corporation, ORDER GRANTING DEFENDANT’S and BARD PERIPHERAL VASCULAR, RENEWED MOTION TO TRANSFER INC., an Arizona corporation, TO THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF Plaintiffs, DELAWARE

v. 2:12-cv-00036-RJS-DAO

SMITHS MEDICAL ASD, INC., a Delaware Chief District Judge Robert J. Shelby corporation, Magistrate Judge Daphne A. Oberg Defendant.

Plaintiffs C.R. Bard, Inc. and Bard Peripheral Vascular, Inc. (collectively, Bard)1 develop and manufacture medical devices. Bard filed suit claiming Defendant Smiths Medical ASD, Inc. (Smiths) infringed on two of Bard’s patents. Smiths denies the allegations. Before the court is Smiths’s Renewed Motion to Transfer for Improper Venue.2 For the reasons explained below, the Motion is GRANTED, and the case is TRANSFERRED to the District of Delaware. BACKGROUND Bard commenced this action on January 11, 2012, alleging Smiths infringed two of Bard’s patents related to its power injectable port technology.3 Bard concurrently filed in this

1 On July 12, 2017, C.R. Bard assigned the patents at issue in this case to Bard Peripheral Vascular, including all causes of action for past, present, and future infringement claims. See Dkt. 122 (Motion to Substitute a Party) at 2. C.R. Bard then moved the court to substitute Bard Peripheral Vascular as the named Plaintiff in this case. Id. The court denied the Motion and instead ordered joinder of C.R. Bard and Bard Peripheral Vascular. See Dkt. 140 (Order Denying Substitution). 2 Dkt. 204. 3 Dkt. 2 (Complaint) at 2–4 (U.S. Patent No. 7,947,022; U.S. Patent No. 7,785,302). court two other actions involving the same patents against Medical Components, Inc. and AngioDynamics, Inc.4 While the cases were in initial proceedings, AngioDynamics filed with the United States Patent & Trademark Office (USPTO) a petition for inter partes reexamination.5 After the USPTO granted the petition for review, Smiths successfully moved to stay this case.6 On December 17, 2012, the case was administratively closed.7 Upon completion of the

USPTO’s inter partes reexamination proceedings, the court on October 4, 2019 lifted the stay and reopened the case.8 While the case was stayed, the Supreme Court decided TC Heartland LLC v. Kraft Foods Group Brands LLC, holding that for venue purposes a corporate defendant in a patent infringement action resides only in its state of incorporation.9 That holding significantly changed existing law.10 Shortly after this case was reopened, Smiths moved to transfer under the new rule announced in TC Heartland.11 Smiths argued transfer was required because it is incorporated, and therefore resides, in Delaware, and it does not have a regular and established place of

4 See cases 2:12-cv-32 and 2:12-cv-35, respectively. 5 See Dkt. 83 (Motion to Stay) at 2. AngioDynamics challenged three of Bard’s patents involving power injectable port technology, but only two of the patents are at issue in this case. See supra note 3. 6 See Dkt. 89 (Motion for Extension of Stay); Dkt. 97 (Order granting stay). 7 See Dkt. 98. 8 See Dkt. 152. 9 137 S. Ct. 1514, 1517 (2017). 10 See In re Micron Technology, Inc., 875 F.3d 1091, 1094 (Fed. Cir. 2017). 11 See Dkt 157 (Motion to Transfer). business in Utah.12 Challenging that assertion, Bard filed a motion for venue discovery,13 which the court granted.14 Following venue discovery, Smiths filed a Renewed Motion to Transfer for Improper Venue, which is now before the court.15 Bard opposes the Motion, arguing venue is proper in the

District of Utah because (1) Smiths waived its ability to challenge venue in 2012 when it affirmatively stated in its Answer that venue here was proper and then filed counterclaims against Bard, and (2) the home offices of two Utah-based Smiths sales representatives and a Utah storage unit paid for and used by Smiths sales representatives proves that Smiths had a regular and established place of business in Utah at the time this lawsuit was filed.16 The court concludes venue in the District of Utah is improper and GRANTS Smiths’s Renewed Motion to Transfer. DISCUSSION “Upon motion by the Defendant challenging venue in a patent case, the Plaintiff bears the burden of establishing proper venue.”17 Venue is established under 28 U.S.C. § 1400(b), which

provides: “[a]ny civil action for patent infringement may be brought in the judicial district where the defendant resides, or where the defendant has committed acts of infringement and has a regular and established place of business.” The Supreme Court recently held in TC Heartland that in the context of a patent infringement action, a corporate defendant resides only in its state

12 Id. at 4. 13 Dkt. 161. 14 Dkt. 168 (Order granting venue discovery). 15 Dkt. 204. 16 See Dkt. 214 (Opposition Memo.) at 1. 17 In re ZTE (USA) Inc., 890 F.3d 1008, 1013 (Fed. Cir. 2018). of incorporation.18 Smiths asserts venue is no longer proper in the District of Utah under TC Heartland because it is incorporated, and thus resides, in Delaware. For that reason, Smiths maintains venue here is proper only if Smiths has committed acts of infringement in Utah and had “a regular and established place of business” in the state when the case was filed in 2012.19 Smiths denies it had such a place of business.

Bard argues venue is proper in the District of Utah because (1) Smiths waived its right to challenge venue, and (2) Smiths had a regular and established place of business in the District when the case was filed. The court addresses each argument in turn. I. Smiths Did Not Waive Its Right to Challenge Venue Bard first argues Smiths waived its right to challenge venue because it admitted in its Answer to the 2012 Complaint that venue here was appropriate, and because it sought affirmative relief here when it chose to assert counterclaims against Bard. The court disagrees. A. Legal Standard Patent venue law has changed substantially over the past fifty years, with numerous

courts evaluating the relationship between the patent venue statute, § 1400(b), and the general venue statute, 28 U.S.C. § 1391(c).20 In 1957, the Supreme Court held the then-existing version of § 1391(c) did not apply to § 1400(b), meaning that patent venue was separate and distinct from general venue requirements.21 Following 1988 Congressional amendments to § 1391(c),

18 137 S.Ct. at 1517. 19 28 U.S.C. § 1400(b) (2018). 20 Section 1391(c)(2), as most recently amended in 2011, states, “[A]n entity with the capacity to sue and be sued in its common name under applicable law, whether or not incorporated, shall be deemed to reside, if a defendant, in any judicial district in which such defendant is subject to the court’s personal jurisdiction . . . .” 21 See Fourco Glass Co. v. Transmirra Products Corp., 353 U.S. 222, 229 (1957). the Federal Circuit concluded in V.E. Holding Corp. v. Johnson Gas Appliance Co.22 that the new § 1391 amendments “furnished a definition of ‘resides’ that applied to § 1400(b).”23 Under the new amendments, a corporate defendant was “deemed to reside in any judicial district in which it [wa]s subject to personal jurisdiction at the time the action [wa]s commenced.”24 Crucially, the

court in V.E.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

The Fair v. Kohler Die & Specialty Co.
228 U.S. 22 (Supreme Court, 1913)
Stonite Products Co. v. Melvin Lloyd Co.
315 U.S. 561 (Supreme Court, 1942)
Fourco Glass Co. v. Transmirra Products Corp.
353 U.S. 222 (Supreme Court, 1957)
Schnell v. Peter Eckrich & Sons, Inc.
365 U.S. 260 (Supreme Court, 1961)
Rates Technology, Inc. v. Nortel Networks Corp.
399 F.3d 1302 (Federal Circuit, 2005)
In Re Cordis Corporation
769 F.2d 733 (Federal Circuit, 1985)
Ve Holding Corporation v. Johnson Gas Appliance Company
917 F.2d 1574 (Federal Circuit, 1990)
In Re: Tc Heartland LLC
821 F.3d 1338 (Federal Circuit, 2016)
TC Heartland LLC v. Kraft Foods Group Brands LLC
581 U.S. 258 (Supreme Court, 2017)
In Re: Cray Inc.
871 F.3d 1355 (Federal Circuit, 2017)
In Re: Micron Technology, Inc.
875 F.3d 1091 (Federal Circuit, 2017)
Medicines Company v. Hospira, Inc.
881 F.3d 1347 (Federal Circuit, 2018)
In Re: Zte (Usa) Inc.
890 F.3d 1008 (Federal Circuit, 2018)
In Re: Oath Holdings Inc.
908 F.3d 1301 (Federal Circuit, 2018)
Regents of the Univ. of Minn. v. Gilead Scis., Inc.
299 F. Supp. 3d 1034 (D. Maine, 2017)
Regenlab U.S. LLC v. Estar Techs. Ltd.
335 F. Supp. 3d 526 (S.D. Illinois, 2018)
Campbell v. Bartlett
975 F.2d 1569 (Tenth Circuit, 1992)

Cite This Page — Counsel Stack

Bluebook (online)
CR Bard, Inc. v. Smiths Medical ASD, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/cr-bard-inc-v-smiths-medical-asd-inc-ded-2020.